Collegium Pharmaceutical
Abuse-deterrent Pharmaceutical Products for Chronic Pain.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor investor | €0.0 | round |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor | €0.0 | round | |
| investor investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor investor investor investor investor investor investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
* | $646m | Post IPO Debt | |
| Total Funding | 000k | ||
| USD | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | (11 %) | 68 % | 22 % | 11 % | 19 % | 3 % | (7 %) |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | 8 % | 7 % | 59 % | 55 % | 59 % | 56 % | 52 % |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | 26 % | (5 %) | 8 % | 11 % | 8 % | 12 % | 23 % |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 3 % | 1 % | - | - | - | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
Collegium Pharmaceutical is a specialty biopharmaceutical company that focuses on the development and commercialization of medicines for pain management. The company is committed to improving the lives of people living with serious medical conditions through its portfolio of differentiated medications.
Collegium's business model revolves around building a leading, diversified biopharmaceutical company. A key part of its strategy is the growth of its commercial portfolio, with Jornay PM being a primary growth driver. The company emphasizes responsible pain management and is known for its development of products with tamper-resistant features and extended-release delivery systems, utilizing its proprietary technologies.
Operating in the pharmaceutical market, Collegium serves patients and healthcare providers by offering alternative solutions for pain treatment. The company's revenue is generated through the sale of its pharmaceutical products. Collegium is also actively engaged in deploying capital in a disciplined manner to support its growth and expand its portfolio of medications for serious medical conditions.
Keywords: specialty pharmaceutical, pain management, biopharmaceutical, commercialization, medication, tamper-resistant, extended-release, Jornay PM, healthcare, portfolio
Tech stack
Investments by Collegium Pharmaceutical
Edit
